Some telehealth companies are running social media ads promoting drugs for unapproved uses, showing benefits and paid testimonials but not risks or side effects
Context & Ripple Effects
This report closes a loop the coverage has been opening since 2018, when BuzzFeed documented [[a:930191|social networks being used to sell prescription medications despite terms of service banning it]]. The direct-to-consumer model then went mainstream through sites like Hims, which experts flagged in 2019 as a public-health risk, and exploded during the pandemic when looser rules let startups like Cerebral and Done prescribe stimulants after 30-minute online evaluations.
By mid-2022, documents showed Cerebral used social media ads to grow its ADHD drug business while federal prosecutors examined possible Controlled Substance Act violations. Today's finding — ads touting unapproved uses with paid testimonials and no risk disclosure — shows the playbook extended past controlled substances into off-label promotion generally, just as the ketamine-prescribing wave reported in January 2023 widens the population of drugs being marketed this way.
First-order effects
- Telehealth companies running these ads now carry direct legal exposure: promoting unapproved uses without risk disclosure is the kind of conduct behind the federal probe into Cerebral's ADHD advertising, and paid testimonials compound the compliance gap.
- Patients seeing these ads are making medication decisions on benefit claims alone, since risks and side effects are omitted — the exact asymmetry experts warned about when online prescription sites like Hims emerged.
Second-order effects
- Social platforms face pressure to enforce their own health-ad policies more aggressively; their terms already forbid illegal drug sales, yet the ads run, so enforcement failures become a governance liability alongside the advertisers'.
- Rivals such as Hims must choose between matching the aggressive ad spend or differentiating on fuller disclosure, as scrutiny of one player's marketing raises the compliance bar for the whole direct-to-consumer category.
Third-order effects
- If the pattern holds, the sector's growth engine — cheap social acquisition feeding high-volume prescribing — collides with pharmaceutical marketing law, pushing regulators to treat telehealth ad practices as a drug-promotion problem rather than a startup-growth story.
- Sustained enforcement would likely force consolidation around operators who can absorb compliance costs, ending the era in which pandemic-era loosened prescribing rules and unpoliced advertising could be combined into a customer-acquisition strategy.
The trend: Direct-to-consumer telehealth is colliding with pharmaceutical marketing rules as its social-media growth playbook draws escalating federal and platform scrutiny.